城乡链接与农民合作

2009-2010 > Academic research: refereed > Publication in refereed journalVersion of RecordPublishe

An STM study on the Structure of Pt(100)/Ionic Liquid OMIPF6 Interface

本文运用电化学扫描隧道显微术研究了离子液体OMIPF6中Pt（100）表面结构在电化学双层区随电极电位的变化. OMI+阳离子在Pt（100）表面形成有序吸附结构，并且在约1.2 V宽的电位区间内稳定地存在Pt（100）表面。在电位负于-0.6 V时，有序吸附结构会发生向无序吸附结构的转变. 在电位正于+0.6 V时，较强的静电排斥力才能克服OMIPF6与Pt（100）表面之间的化学作用，从而导致OMI+阳离子的脱附. 研究表明，OMI+阳离子具有的较长烷基侧链与Pt金属产生的较强化学相互作用是影响该Pt（100）/ OMIPF6界面结构的重要因素.Potential-dependent structures of Pt(100)/ionic liquid 1-methyl-3-octylimidazolium hexafluorophosphate (OMIPF6) interface have been studied by electrochemical scanning tunneling microscopy (ECSTM). The cation OMI+ forms ordered structure on Pt(100) surface, which exists in a potential region of about 1.2 V. When the potential is more negative than -0.6 V, it can be seen that the ordered structure transforms to disordered structure. When the potential shifts positively to +0.6 V, the desorption of cations OMI+ occurs, which indicates that strong electrostatic repulsion is needed to overcome chemical interaction between OMIPF6 and Pt(100) surface, leading to the desorption. The above results demonstrate that owing to the longer alkyl chain OMI+ can interact strongly with Pt(100), which plays an important role in the structure of Pt(100)/ OMIPF6 interface.国家自然科学基金项目（21373174, 21673193）, 福建省自然科学基金项目（2016J01075）资助作者联系地址：厦门大学化学化工学院，固体表面物理化学国家重点实验室，厦门，361005Author's Address: College of Chemistry and Chemical Engineering, State Key Laboratory for Physical Chemistry of Solid Surfaces, Xiamen University, Xiamen, 361005通讯作者E-mail：jwyan@xmu. edu. cn; [email protected]

一台用于IMP重离子治癌线上的电离室

介绍一种用于中国科学院近代物理研究所(IMP)重离子肿瘤治疗线上、于纵向场常压下工作的气体电离室,其灵敏面积为250mm×250mm,极间距离为10mm,电离室工作气体为P10,在85kPa下流气式工作。用75MeV/u12C离子入射,测量了电离室的坪曲线。发现电离室工作坪区900—3000V,12C的Bragg峰位于13.73mm,峰的极大值半高宽(FWHM)为0.19mm

大连极紫外相干光源

先进光源的发展在前沿科学研究中发挥的作用越来越重要。近十年来,飞速发展的自由电子激光技术为科学家们提供了探索未知世界、发现新科学规律和实现技术变革的重要工具。建成的大连极紫外(EUV)相干光源的运行波段为50~150nm,单脉冲能量大于100μJ,且可提供10-12 s和10-13 s量级的超快激光脉冲,是我国第一台自由电子激光用户装置,并且是国际上唯一运行在极紫外波段的自由电子激光用户装置,在世界范围内为用户提供具有高峰值亮度和超短脉冲的极紫外激光。大连EUV相干光源是由国家自然科学基金委资助、由中国科学院大连化学物理研究所和上海应用物理研究所共同承担的重大科学仪器研制项目,目标是打造一个以先进极紫外光源为核心、主要用于能源基础科学研究的光子科学平台

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials